Biogen beats estimates on Spinraza sales, raises forecast


Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017.



from Biotech News